Aspen raises a $140M IPO in pursuit of a cell therapy for Parkinson’s
Source: BioPharma Dive - Latest News
The San Diego biotechnology startup is one of several firms working on a cutting-edge technique with the potential to slow or even halt the neurodegenerative condition.